As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Release of New Report to Promote Acetaminophen Safety

The Firm is investigating Tylenol lawsuits on behalf of individuals who allegedly suffered severe liver damage due to the acetaminophen in Tylenol-brand over-the-counter medications.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
More than 100 Tylenol liver damage claims are now pending in federal court, all of which allege patients sustained serious liver injuries even after using Tylenol products in accordance with label directions.

New York, New York (PRWEB) July 02, 2014

As Tylenol lawsuits (http://www.tylenollawsuitclaims.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes the release of a new report aimed at promoting acetaminophen safety. According to the document, which was issued last month by the Acetaminophen Awareness Coalition (ACC), acetaminophen is the active ingredient in more than 600 over-the-counter and prescription medicines, including Tylenol-brand products. Among other things, the report explores the successful result of ongoing educational campaigns to encourage appropriate use of these medications, and prevent acetaminophen-induced liver damage.*

“More than 100 Tylenol liver damage claims are now pending in federal court, all of which allege patients sustained serious liver injuries even after using Tylenol products in accordance with label directions. We are pleased that more attention is being brought to this issue by the ACC,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is offering free legal reviews to consumers who were allegedly harmed by a Tylenol-brand over-the-counter medication.

Tylenol Liver Damage
According to a recent article in the Philadelphia Inquirer, acetaminophen is the number-one cause of acute liver failure in the U.S. Some 78,000 people require emergency room care every year due to toxic reactions to Tylenol and other acetaminophen-containing drugs.** In April, the U.S. Food & Drug Administration (FDA) announced that prescription medications containing more than 325 milligrams of acetaminophen were no longer considered safe and were being voluntarily removed from the market.***

The FDA’s new limits on prescription acetaminophen did not apply to over-the-counter products like Tylenol. In August 2013, Bloomberg.com reported that over-the-counter Extra Strength Tylenol caplets each contain 500 mg of acetaminophen. That same month, McNeil Consumer Healthcare announced that it would add new, more prominent warnings regarding the risk of liver damage to the labels of Tylenol-brand medication.****

According to court documents, more than 140 lawsuits involving Tylenol liver damage allegations have been filed in the U.S. District Court, Eastern District of Pennsylvania. In many cases, plaintiffs are alleged to have suffered liver injuries so sever they required hospitalization or liver transplantation. A number of cases also claim that use of a Tylenol product led to fatal liver injuries. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)

Individuals who allegedly suffered acetaminophen-induced liver damage due to a Tylenol-brand over-the-counter medication may be entitled to file their own Tylenol lawsuit. To learn more about the ongoing Tylenol litigation, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.

*knowyourdose.org/sites/default/files/acetaminophen_report.pdf, ACC, June 2014
**articles.philly.com/2014-02-17/news/47382323_1_acetaminophen-poisoning-tylenol-maker-kate-trunk, Philadelphia Inquirer, February 17, 2014
***latimes.com/science/sciencenow/la-sci-sn-extra-strength-acetaminophen-fda-20140428,0,6108401.story, LA Times, April 28, 2014
****bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitclaims.com/
https://plus.google.com/115936073311125306742?rel=author